A One Month, investigator and participant-blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
Study of Remibrutinib (LOU064) in Patients with Peanut Allergy
Sponsor: NOVARTIS Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAU7135
U.S. Govt. ID: NCT05432388
Contact: Yannett Franklin: 212-305-2300 / ym206@cumc.columbia.edu
Additional Study Information: The study population includes up to 110 adult male and female participants ages 18-55 years. Participants may have multiple food allergies but must be peanut allergic in order to be included. Safety assessments will include the following: physical examination, vital signs, laboratory evaluations, and ECG (electrocardiogram).
Do You Qualify?
Are you between the ages of 18-55? Yes No
Do you have an allergy to peanuts or peanut-containing foods? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Yannett Franklin